
|Videos|December 6, 2021
Adverse pathology predicts metastasis, death in patients with prostate cancer
Author(s)Urology Times staff
“Adverse pathology is a clear predictor of long-term outcomes for patients,” says Eric A. Klein, MD.
Advertisement
In this video, Eric A. Klein, MD, discusses the background and findings of the recent Urologic Oncology: Seminars and Original Investigations study, Validating the association of adverse pathology with distant metastasis and prostate cancer mortality 20-years after radical prostatectomy, for which he served as senior author. Klein is the emeritus chair of the Cleveland Clinic Glickman Urological & Kidney Institute.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
Clinical Application of MMAI Score in Patients with Prostate Cancer
2
Published data show DFS benefit with aglatimagene besadenovec in localized prostate cancer
3
FDA approves generic Ga-68 PSMA-11 radiodiagnostic for prostate cancer
4
Nicole L. Miller, MD, FACS, on assessing patients after BPH treatment failure
5










